Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.

Szczegóły
Abstrakt

Tytuł:: Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.
Autorzy:: Nobile-Orazio E; 'Giorgio Spagnol' Service of Clinical Neuroimmunology, Department of Neurological Sciences, Dino Ferrari Centre, Milan University, IRCCS Ospedale Maggiore Policlinico, Milan, Italy. />Cappellari A
Meucci N
Carpo M
Terenghi F
Bersano A
Priori A
Barbieri S
Scarlato G
Źródło:: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2002 Jun; Vol. 72 (6), pp. 761-6.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: London : BMJ Publishing Group
Original Publication: London : British Medical Association
MeSH Terms:: Neural Conduction*
Immunoglobulins, Intravenous/*therapeutic use
Motor Neuron Disease/*drug therapy
Motor Neuron Disease/*immunology
Adult ; Diagnosis, Differential ; Disease Progression ; Female ; Humans ; Immunoglobulins, Intravenous/immunology ; Immunoglobulins, Intravenous/pharmacology ; Male ; Middle Aged ; Motor Neuron Disease/diagnosis ; Treatment Outcome
References:: Neurology. 1999 Dec 10;53(9):2206-7. (PMID: 10599811)
Neurology. 1995 Aug;45(8):1570-7. (PMID: 7644057)
Neurology. 2000 Nov 14;55(9):1256-62. (PMID: 11087764)
Brain. 2001 Jan;124(Pt 1):145-53. (PMID: 11133794)
Ann Neurol. 2000 Dec;48(6):919-26. (PMID: 11117549)
J Neuroimmunol. 2001 Apr 2;115(1-2):4-18. (PMID: 11282149)
Neuromuscul Disord. 2001 Apr;11(3):309-14. (PMID: 11297948)
Eur Neurol. 1986;25(6):416-23. (PMID: 3024989)
Muscle Nerve. 1988 Feb;11(2):103-7. (PMID: 3343985)
Ann Neurol. 1988 Jul;24(1):73-8. (PMID: 2843079)
Ann Neurol. 1990 Aug;28(2):146-56. (PMID: 2221844)
Adv Neurol. 1991;56:399-403. (PMID: 1853773)
Neurology. 1993 Mar;43(3 Pt 1):537-44. (PMID: 8450997)
Ann Neurol. 1993 Mar;33(3):237-42. (PMID: 8498806)
Muscle Nerve. 1993 Sep;16(9):896-903. (PMID: 8355720)
Muscle Nerve. 1994 Jan;17(1):100-4. (PMID: 8264687)
Ann Neurol. 1995 May;37 Suppl 1:S43-50. (PMID: 8968216)
J Neurol. 1997 Mar;244(3):143-52. (PMID: 9050954)
Neurology. 1997 Mar;48(3):700-7. (PMID: 9065551)
J Neurol. 1997 Oct;244(10):625-30. (PMID: 9402538)
J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):765-9. (PMID: 9416813)
Muscle Nerve. 1998 Feb;21(2):243-5. (PMID: 9466602)
Muscle Nerve Suppl. 1999;8:S225-9. (PMID: 16921636)
Muscle Nerve. 2000 Jun;23(6):900-8. (PMID: 10842266)
Substance Nomenclature:: 0 (Immunoglobulins, Intravenous)
Entry Date(s):: Date Created: 20020523 Date Completed: 20020625 Latest Revision: 20190501
Update Code:: 20240104
PubMed Central ID:: PMC1737926
DOI:: 10.1136/jnnp.72.6.761
PMID:: 12023421
: Czasopismo naukowe

Objective: To determine whether patients with clinically typical multifocal motor neuropathy (MMN) with or without definite or probable conduction block (CB) differ in terms of clinical presentation, immunological findings, or response to treatment with intravenous immunoglobulin (IVIg).
Methods: 23 consecutive patients were studied with the typical clinical features of MMN, consisting of a progressive multineuropathic motor impairment with minimal or no sensory loss. In 14 patients, electrophysiological studies disclosed the presence of a definite or probable CB according to the criteria proposed by the American Association of Electrodiagnostic Medicine (AAEM) in at least one motor nerve. Six patients had possible CB, defined as a degree of CB 10% less than that required by the AAEM for probable CB, while no CB was detected in three patients.
Results: Patients with possible CB did not differ from those with a definite or probable CB in terms of age at disease onset (mean 38.8 v 38.2 years, respectively), distribution and severity of limb weakness, clinical impairment (mean Rankin score 2.2 in both), and frequency of antiganglioside antibodies (33% v 29%). Patients with possible CB had a longer mean disease duration (9 v 5.9 years, p < 0.05) and a less frequent consistent response to IVIg (67% v 86%) than those with a definite or probable CB. Patients without a detectable CB had a similar frequency of antiganglioside antibodies (33%) but had a longer disease duration (20.3 years), greater impairment (Rankin score 2.7), and more frequent signs of axonal degeneration (41% of examined motor nerves) than patients with CB (13-15%, p < 0.005). Only one patient without detectable CB (33%) consistently improved with IVIg.
Conclusions: Patients with possible CB were clinically and immunologically indistinguishable from those with definite or probable CB, albeit with a slightly less frequent response to IVIg. This finding suggests that failure to fulfil AAEM criteria for CB in patients with otherwise clinically typical MMN should not preclude this diagnosis and consequently a treatment trial with IVIg. Whether the longer duration and greater severity of the disease and more frequent axonal impairment in patients without detectable CB than in those with CB explain their lower response to IVIg remains to be established.

Informacja